Timothy Kieffer
Technik-/Wissenschafts-/F&E-Leiter bei FRACTYL HEALTH, INC.
Vermögen: - $ am 30.04.2024
Profil
Timothy Kieffer is currently the Chief Scientific Officer at Fractyl Health, Inc. He previously held the position of Chief Scientific Officer at ViaCyte, Inc. from 2021 to 2022.
Prior to his industry roles, he worked as a Professor at the University of British Columbia.
Dr. Kieffer obtained a doctorate degree from the University of British Columbia.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
FRACTYL HEALTH, INC.
-.--% | 15.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Timothy Kieffer
| Unternehmen | Position | Beginn |
|---|---|---|
| FRACTYL HEALTH, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2023 |
Ehemalige bekannte Positionen von Timothy Kieffer
| Unternehmen | Position | Ende |
|---|---|---|
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2022 |
| University of British Columbia | Corporate Officer/Principal | - |
Ausbildung von Timothy Kieffer
| University of British Columbia | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| FRACTYL HEALTH, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
